{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T01:42:31Z","timestamp":1768786951203,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s12325-023-02763-z","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T04:53:36Z","timestamp":1706849616000},"page":"915-927","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Evolving Role of PD-(L)1 Inhibition in Optimizing Outcomes for High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC): A Podcast"],"prefix":"10.1007","volume":"41","author":[{"given":"Peter C.","family":"Black","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard J.","family":"Eigl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,2]]},"reference":[{"key":"2763_CR1","first-page":"15","volume":"8","author":"K Saginala","year":"2020","unstructured":"Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of bladder cancer. Med Sci (Basel). 2020;8:15.","journal-title":"Med Sci (Basel)"},{"key":"2763_CR2","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.urolonc.2021.05.015","volume":"39","author":"ND Shore","year":"2021","unstructured":"Shore ND, Palou Redorta J, Robert G, et al. Non-muscle-invasive bladder cancer: an overview of potential new treatment options. Urol Oncol. 2021;39:642\u201363.","journal-title":"Urol Oncol"},{"key":"2763_CR3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.currproblcancer.2014.06.001","volume":"38","author":"JC Park","year":"2014","unstructured":"Park JC, Citrin DE, Agarwal PK, Apolo AB. Multimodal management of muscle-invasive bladder cancer. Curr Probl Cancer. 2014;38:80\u2013108.","journal-title":"Curr Probl Cancer"},{"key":"2763_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.14740\/wjon1210","volume":"10","author":"A Cassell","year":"2019","unstructured":"Cassell A, Yunusa B, Jalloh M, et al. Non-muscle invasive bladder cancer: a review of the current trend in Africa. World J Oncol. 2019;10:123\u201331.","journal-title":"World J Oncol"},{"key":"2763_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O, et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol. 2022;81:75\u201394.","journal-title":"Eur Urol"},{"key":"2763_CR6","first-page":"43","volume":"22","author":"RS Matulewicz","year":"2020","unstructured":"Matulewicz RS, Steinberg GD. Non-muscle-invasive bladder cancer: overview and contemporary treatment landscape of neoadjuvant chemoablative therapies. Rev Urol. 2020;22:43\u201351.","journal-title":"Rev Urol"},{"key":"2763_CR7","doi-asserted-by":"publisher","first-page":"S193","DOI":"10.5489\/cuaj.1195","volume":"3","author":"V Chalasani","year":"2009","unstructured":"Chalasani V, Chin JL, Izawa JI. Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer. Can Urol Assoc J. 2009;3:S193\u20138.","journal-title":"Can Urol Assoc J"},{"key":"2763_CR8","doi-asserted-by":"publisher","first-page":"9743","DOI":"10.1038\/s41598-020-66747-7","volume":"10","author":"CC Guo","year":"2020","unstructured":"Guo CC, Bondaruk J, Yao H, et al. Assessment of luminal and basal phenotypes in bladder cancer. Sci Rep. 2020;10:9743.","journal-title":"Sci Rep"},{"key":"2763_CR9","doi-asserted-by":"publisher","first-page":"5670","DOI":"10.3390\/ijms21165670","volume":"21","author":"M Minoli","year":"2020","unstructured":"Minoli M, Kiener M, Thalmann GN, Kruithof-de Julio M, Seiler R. Evolution of urothelial bladder cancer in the context of molecular classifications. Int J Mol Sci. 2020;21:5670.","journal-title":"Int J Mol Sci"},{"key":"2763_CR10","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1002\/ijc.32737","volume":"146","author":"G Sj\u00f6dahl","year":"2020","unstructured":"Sj\u00f6dahl G, Eriksson P, Patschan O, et al. Molecular changes during progression from nonmuscle invasive to advanced urothelial carcinoma. Int J Cancer. 2020;146:2636\u201347.","journal-title":"Int J Cancer"},{"key":"2763_CR11","first-page":"108","volume":"34","author":"A Homami","year":"2020","unstructured":"Homami A, Ataei Kachoei Z, Asgarie M, Ghazi F. Analysis of FGFR3 and HRAS genes in patients with bladder cancer. Med J Islam Repub Iran. 2020;34:108.","journal-title":"Med J Islam Repub Iran"},{"key":"2763_CR12","doi-asserted-by":"publisher","first-page":"283","DOI":"10.4103\/0970-1591.166449","volume":"31","author":"A Soubra","year":"2015","unstructured":"Soubra A, Risk MC. Diagnostics techniques in nonmuscle invasive bladder cancer. Indian J Urol. 2015;31:283\u20138.","journal-title":"Indian J Urol"},{"key":"2763_CR13","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.3390\/cancers13061396","volume":"13","author":"VK Wong","year":"2021","unstructured":"Wong VK, Ganeshan D, Jensen CT, Devine CE. Imaging and management of bladder cancer. Cancers (Basel). 2021;13:1396.","journal-title":"Cancers (Basel)"},{"key":"2763_CR14","doi-asserted-by":"publisher","first-page":"E115","DOI":"10.5489\/cuaj.6378","volume":"14","author":"W Kassouf","year":"2020","unstructured":"Kassouf W, Aprikian A, Saad F, et al. Continuing towards optimization of bladder cancer care in Canada: summary of the third Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting. Can Urol Assoc J. 2020;14:E115\u201325.","journal-title":"Can Urol Assoc J"},{"key":"2763_CR15","doi-asserted-by":"publisher","first-page":"E281","DOI":"10.5489\/cuaj.5246","volume":"12","author":"W Kassouf","year":"2018","unstructured":"Kassouf W, Aprikian A, Saad F, et al. Improving patient journey and quality of care: summary from the second Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting. Can Urol Assoc J. 2018;12:E281\u201397.","journal-title":"Can Urol Assoc J"},{"key":"2763_CR16","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","volume":"196","author":"S Chang","year":"2016","unstructured":"Chang S, Boorjian S, Chou R, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline. J Urol. 2016;196:1021.","journal-title":"J Urol"},{"key":"2763_CR17","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.1007\/s00345-021-03666-w","volume":"39","author":"C Lebacle","year":"2021","unstructured":"Lebacle C, Loriot Y, Irani J. BCG-unresponsive high-grade non-muscle invasive bladder cancer: what does the practicing urologist need to know? World J Urol. 2021;39:4037\u201346.","journal-title":"World J Urol"},{"key":"2763_CR18","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41585-021-00481-1","volume":"18","author":"N Lobo","year":"2021","unstructured":"Lobo N, Brooks NA, Zlotta AR, et al. 100 years of Bacillus Calmette-Gu\u00e9rin immunotherapy: from cattle to COVID-19. Nat Rev Urol. 2021;18:611\u201322.","journal-title":"Nat Rev Urol"},{"key":"2763_CR19","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/bju.13146","volume":"117","author":"M Moschini","year":"2016","unstructured":"Moschini M, Sharma V, Dell\u2019oglio P, et al. Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy. BJU Int. 2016;117:604\u201310.","journal-title":"BJU Int"},{"key":"2763_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.urology.2018.04.039","volume":"118","author":"S Tapiero","year":"2018","unstructured":"Tapiero S, Helfand A, Kedar D, et al. Patient compliance with maintenance intravesical therapy for nonmuscle invasive bladder cancer. Urology. 2018;118:107\u201313.","journal-title":"Urology"},{"key":"2763_CR21","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/cncr.30392","volume":"123","author":"VT Packiam","year":"2017","unstructured":"Packiam VT, Johnson SC, Steinberg GD. Non-muscle-invasive bladder cancer: intravesical treatments beyond Bacille Calmette-Gu\u00e9rin. Cancer. 2017;123:390\u2013400.","journal-title":"Cancer"},{"key":"2763_CR22","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.2147\/OTT.S165840","volume":"11","author":"Y Wang","year":"2018","unstructured":"Wang Y, Liu J, Yang X, et al. Bacillus Calmette-Gu\u00e9rin and anti-PD-L1 combination therapy boosts immune response against bladder cancer. Onco Targets Ther. 2018;11:2891\u20139.","journal-title":"Onco Targets Ther"},{"key":"2763_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110393","volume":"129","author":"J Han","year":"2020","unstructured":"Han J, Gu X, Li Y, Wu Q. Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect. Biomed Pharmacother. 2020;129:110393.","journal-title":"Biomed Pharmacother"},{"key":"2763_CR24","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.3390\/ijms22062800","volume":"22","author":"FC de Jong","year":"2021","unstructured":"de Jong FC, Rutten VC, Zuiverloon TCM, Theodorescu D. Improving anti-PD-1\/PD-L1 therapy for localized bladder cancer. Int J Mol Sci. 2021;22:2800.","journal-title":"Int J Mol Sci"},{"key":"2763_CR25","doi-asserted-by":"publisher","first-page":"5973","DOI":"10.2147\/OTT.S135157","volume":"11","author":"DD Stenehjem","year":"2018","unstructured":"Stenehjem DD, Tran D, Nkrumah MA, Gupta S. PD1\/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer. Onco Targets Ther. 2018;11:5973\u201389.","journal-title":"Onco Targets Ther"},{"key":"2763_CR26","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","volume":"22","author":"AV Balar","year":"2021","unstructured":"Balar AV, Kamat AM, Kulkarni GS, et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 2021;22:919\u201330.","journal-title":"Lancet Oncol"},{"key":"2763_CR27","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3389\/fimmu.2020.00339","volume":"11","author":"Y Jiang","year":"2020","unstructured":"Jiang Y, Zhao X, Fu J, Wang H. Progress and challenges in precise treatment of tumors with PD-1\/PD-L1 blockade. Front Immunol. 2020;11:339.","journal-title":"Front Immunol"},{"key":"2763_CR28","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/bju.15495","volume":"128","author":"DA Winters","year":"2021","unstructured":"Winters DA, Soukup T, Sevdalis N, Green JSA, Lamb BW. The cancer multidisciplinary team meeting: in need of change? History, challenges and future perspectives. BJU Int. 2021;128:271\u20139.","journal-title":"BJU Int"},{"key":"2763_CR29","unstructured":"Gomella LG, Chang SS. Treatment journey for a patient with bladder cancer. Urology Times. 2022. https:\/\/www.urologytimes.com\/view\/treatment-journey-for-a-patient-with-bladder-cancer. Accessed 14 June 2023."},{"key":"2763_CR30","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3389\/fphar.2017.00730","volume":"8","author":"P-F Wang","year":"2017","unstructured":"Wang P-F, Chen Y, Song SY, et al. Immune-related adverse events associated with anti-PD-1\/PD-L1 treatment for malignancies: a meta-analysis. Front Pharmacol. 2017;8:730.","journal-title":"Front Pharmacol"},{"key":"2763_CR31","doi-asserted-by":"publisher","first-page":"E40","DOI":"10.1503\/cmaj.180870","volume":"191","author":"K Esfahani","year":"2019","unstructured":"Esfahani K, Meti N, Miller WH Jr, Hudson M. Adverse events associated with immune checkpoint inhibitor treatment for cancer. CMAJ. 2019;191:E40\u20136.","journal-title":"CMAJ"},{"key":"2763_CR32","doi-asserted-by":"crossref","unstructured":"Koch GE, Smelser WW, Chang SS. Side effects of intravesical BCG and chemotherapy for bladder cancer: what they are and how to manage them. Urology. 2021;149:11\u201320.","DOI":"10.1016\/j.urology.2020.10.039"},{"key":"2763_CR33","doi-asserted-by":"crossref","unstructured":"van der Meijden APM, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV. Maintenance bacillus calmette-guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European organisation for research and treatment of cancer genito-urinary group phase III trial. Eur. Urol. 2003;44:429\u201334.","DOI":"10.1016\/S0302-2838(03)00357-9"},{"key":"2763_CR34","doi-asserted-by":"crossref","unstructured":"Brausi M, Oddens J, Sylvester R, et al. Side effects of bacillus calmette-gu\u00e9rin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur. Urol. 2014;65:69\u201376.","DOI":"10.1016\/j.eururo.2013.07.021"},{"key":"2763_CR35","doi-asserted-by":"crossref","unstructured":"Lamm DL, Blumenstein BA, David Crawford E, et al. Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study. Urol. Oncol. Semin. Orig. Invest. 1995;1:119\u201326.","DOI":"10.1016\/1078-1439(95)00041-F"},{"key":"2763_CR36","doi-asserted-by":"crossref","unstructured":"Shang PF, Kwong J, Wang ZP, et al. Intravesical bacillus calmette-gu\u00e9rin versus epirubicin for Ta and T1 bladder cancer. Cochrane Database Syst. Rev. 2011.","DOI":"10.1002\/14651858.CD006885.pub2"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02763-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02763-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02763-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T18:15:40Z","timestamp":1708452940000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02763-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,2]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["2763"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02763-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,2]]},"assertion":[{"value":"5 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Peter C. Black is a member of an advisory board or equivalent with a commercial organization: AbbVie, AstraZeneca, Astellas, Bayer, BMS, EMD-Serono, Ferring, Fergene, Janssen, Merck, miR Scientific, Nonagen, NanOlogy, Pfizer, Photocure, Prokarium, Protara Therapeutics, QED Bioscience, Roche, Sanofi, Sesen Bio, STIMIT, TerSera, Tolmar, Urogen, and Verity; is a member of a Speaker\u2019s bureau: Janssen, Minogue, Ferring, TerSera, and Pfizer; has received a grant(s) or an honorarium from a commercial organization: iProgen; is currently participating in or has participated in a clinical trial within the past 2 years: Genentech, Janssen, BMS, AstraZeneca, Therelase, Pacific Edge, and Pfizer; and shares a patent with: Veracyte. He has no other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity. Bernhard J. Eigl has received honoraria from: BMS, Janssen, EMD Serono, Seagen, Gilead; and has received honoraria and research funding from: Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}